CLDX — Celldex Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $2.07bn
- $1.55bn
- $1.55m
Annual cashflow statement for Celldex Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -70.5 | -112 | -141 | -158 | -259 |
| Depreciation | |||||
| Non-Cash Items | 7.59 | 9.6 | 17.7 | 18.5 | 30.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.05 | -3.9 | 13.5 | -21.6 | 14.1 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -60.9 | -104 | -107 | -158 | -211 |
| Capital Expenditures | -1.25 | -1.83 | -1.82 | -1.92 | -2.71 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -215 | 91.8 | -104 | -288 | 212 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -216 | 89.9 | -106 | -290 | 209 |
| Financing Cash Flow Items | 2.48 | 4.08 | 2.24 | 9.15 | 2.39 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 272 | 4.08 | 218 | 441 | 2.39 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -4.69 | -9.71 | 5.38 | -6.46 | 0.515 |